It illuminated the significant discordance of clinicopathological features and prognosis between ER+/PR− phenotype and ER+/PR+ phenotype in IBC, which indicated the necessity that stronger treatments should be applied to patients with ER+/PR− IBC. The gene discussed is PGR; the disease is inflammatory breast carcinoma.